{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:31:31Z","timestamp":1792099891110,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s11739-024-03766-6","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T12:02:33Z","timestamp":1726488153000},"page":"131-138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anakinra in the management of adult-onset still\u2019s disease: a single-center experience"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3804-9800","authenticated-orcid":false,"given":"Berkay","family":"Kilic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4919-4710","authenticated-orcid":false,"given":"Kerem","family":"Parlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2587-4707","authenticated-orcid":false,"given":"Sejla","family":"Karup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7224-087X","authenticated-orcid":false,"given":"Admir","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kardelen","family":"Karaahmetli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9561-2282","authenticated-orcid":false,"given":"Serdal","family":"Ugurlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"issue":"2","key":"3766_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/1744666X.2019.1707664","volume":"16","author":"P Sfriso","year":"2020","unstructured":"Sfriso P, Bindoli S, Doria A, Feist E, Galozzi P (2020) Canakinumab for the treatment of adult-onset Still\u2019s disease. Expert Rev Clin Immunol 16(2):129\u2013138","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"3766_CR2","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.semarthrit.2021.06.004","volume":"51","author":"P Efthimiou","year":"2021","unstructured":"Efthimiou P, Kontzias A, Hur P, Rodha K, Ramakrishna GS, Nakasato P (2021) Adult-onset Still\u2019s disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. Semin Arthritis Rheum 51(4):858\u2013874","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"3766_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/MD.0000000000000021","volume":"93","author":"M Gerfaud-Valentin","year":"2014","unstructured":"Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I et al (2014) Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore) 93(2):91\u201399","journal-title":"Medicine (Baltimore)"},{"key":"3766_CR4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2023-0995","author":"P Ruscitti","year":"2024","unstructured":"Ruscitti P, McGonagle D, Garcia VC, Rabijns H, Toennessen K, Chappell M et al (2024) Systematic review and meta-analysis of pharmacological interventions in adult-onset Still\u2019s disease highlights the beneficial role of biologic DMARDs. J Rheumatol. https:\/\/doi.org\/10.3899\/jrheum.2023-0995","journal-title":"J Rheumatol."},{"key":"3766_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead461","author":"HL Leavis","year":"2023","unstructured":"Leavis HL, van Daele PLA, Mulders-Manders C, Michels R, Rutgers A, Legger E et al (2023) Management of adult-onset Still\u2019s disease: evidence- and consensus-based recommendations by experts. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/kead461","journal-title":"Rheumatology."},{"key":"3766_CR6","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.2299230","author":"K Parlar","year":"2023","unstructured":"Parlar K, Ates MB, Egeli BH, Ugurlu S (2023) The clinical role of anakinra in the armamentarium against familial Mediterranean fever. Expert Rev Clin Immunol. https:\/\/doi.org\/10.1080\/1744666X.2023.2299230","journal-title":"Expert Rev Clin Immunol."},{"key":"3766_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3389\/fphar.2017.00369","volume":"8","author":"S Colafrancesco","year":"2017","unstructured":"Colafrancesco S, Priori R, Valesini G, Argolini L, Baldissera E, Bartoloni E et al (2017) Response to interleukin-1 inhibitors in 140 italian patients with adult-onset still\u2019s disease: a multicentre retrospective observational study. Front Pharmacol 8:369","journal-title":"Front Pharmacol"},{"issue":"6","key":"3766_CR8","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/ard.2006.066381","volume":"66","author":"GD Kalliolias","year":"2007","unstructured":"Kalliolias GD, Georgiou PE, Antonopoulos IA, Andonopoulos AP, Liossis SN (2007) Anakinra treatment in patients with adult-onset Still\u2019s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis 66(6):842\u2013843","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3766_CR9","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP (2008) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61(4):344\u2013349","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"3766_CR10","first-page":"424","volume":"19","author":"M Yamaguchi","year":"1992","unstructured":"Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H et al (1992) Preliminary criteria for classification of adult Still\u2019s disease. J Rheumatol 19(3):424\u2013430","journal-title":"J Rheumatol"},{"issue":"10","key":"3766_CR11","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.3899\/jrheum.111549","volume":"39","author":"D Nordstr\u00f6m","year":"2012","unstructured":"Nordstr\u00f6m D, Knight A, Luukkainen R, van Vollenhoven R, Rantalaiho V, Kajalainen A et al (2012) Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still\u2019s disease. An open, randomized, multicenter study. J Rheumatol. 39(10):2008\u20132011","journal-title":"J Rheumatol."},{"issue":"3","key":"3766_CR12","doi-asserted-by":"publisher","first-page":"R91","DOI":"10.1186\/ar3366","volume":"13","author":"K Laskari","year":"2011","unstructured":"Laskari K, Tzioufas AG, Moutsopoulos HM (2011) Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still\u2019s disease: a case-series study. Arthritis Res Ther 13(3):R91","journal-title":"Arthritis Res Ther"},{"key":"3766_CR13","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3389\/fphar.2016.00380","volume":"7","author":"A Vitale","year":"2016","unstructured":"Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, Cattalini M et al (2016) A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study. Front Pharmacol 7:380","journal-title":"Front Pharmacol"},{"issue":"7","key":"3766_CR14","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s10067-016-3308-8","volume":"35","author":"P Sfriso","year":"2016","unstructured":"Sfriso P, Priori R, Valesini G, Rossi S, Montecucco CM, D\u2019Ascanio A et al (2016) Adult-onset Still\u2019s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clin Rheumatol 35(7):1683\u20131689","journal-title":"Clin Rheumatol"},{"key":"3766_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13023-015-0228-7","volume":"10","author":"L Rossi-Semerano","year":"2015","unstructured":"Rossi-Semerano L, Fautrel B, Wendling D, Hachulla E, Galeotti C, Semerano L et al (2015) Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis 10:19","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"3766_CR16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3109\/03009742.2014.992949","volume":"44","author":"G Cavalli","year":"2015","unstructured":"Cavalli G, Franchini S, Aiello P, Guglielmi B, Berti A, Campochiaro C et al (2015) Efficacy and safety of biological agents in adult-onset Still\u2019s disease. Scand J Rheumatol 44(4):309\u2013314","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"3766_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13075-019-1838-6","volume":"21","author":"F Vercruysse","year":"2019","unstructured":"Vercruysse F, Barnetche T, Lazaro E, Shipley E, Lifermann F, Balageas A et al (2019) Adult-onset still\u2019s disease biological treatment strategy may depend on the phenotypic dichotomy. Arthritis Res Ther 21(1):53","journal-title":"Arthritis Res Ther"},{"key":"3766_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae295","author":"B Kilic","year":"2024","unstructured":"Kilic B, Ozturk A, Karup S, Hacioglu E, Ugurlu S (2024) Efficacy and safety of biologic drugs in Still\u2019s disease: a systematic review and network meta-analysis of randomized controlled trials. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keae295","journal-title":"Rheumatology."},{"key":"3766_CR19","doi-asserted-by":"crossref","unstructured":"Vasques Godinho FM, Parreira Santos MJ, Canas da Silva J (2005) Refractory adult onset Still's disease successfully treated with anakinra. Ann Rheum Dis 64(4):647\u2013648.","DOI":"10.1136\/ard.2004.026617"},{"issue":"8","key":"3766_CR20","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1136\/annrheumdis-2020-217155","volume":"79","author":"C Kedor","year":"2020","unstructured":"Kedor C, Listing J, Zernicke J, Wei\u00df A, Behrens F, Blank N et al (2020) Canakinumab for treatment of adult-onset still\u2019s disease to achieve reduction of arthritic manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Ann Rheum Dis 79(8):1090\u20131097","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"3766_CR21","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","volume":"77","author":"Y Kaneko","year":"2018","unstructured":"Kaneko Y, Kameda H, Ikeda K, Ishii T, Murakami K, Takamatsu H et al (2018) Tocilizumab in patients with adult-onset still\u2019s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis 77(12):1720\u20131729","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3766_CR22","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s10067-024-06905-8","volume":"43","author":"S Suzuki","year":"2024","unstructured":"Suzuki S, Kataoka Y, Otani T, Taniguchi Y, Ikeda K, Tamura N et al (2024) Optimal time of starting tocilizumab in acute phase of adult-onset Still\u2019s disease and comparison of its efficacy with that of methotrexate: a case series and a review of the literature. Clin Rheumatol 43(3):1245\u20131251","journal-title":"Clin Rheumatol"},{"key":"3766_CR23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fmed.2020.00042","volume":"7","author":"A Vitale","year":"2020","unstructured":"Vitale A, Cavalli G, Ruscitti P, Sota J, Colafrancesco S, Priori R et al (2020) Comparison of early vs. delayed anakinra treatment in patients with adult onset still\u2019s disease and effect on clinical and laboratory Outcomes. Front Med (Lausanne). 7:42","journal-title":"Front Med (Lausanne)."},{"issue":"39","key":"3766_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001554","volume":"94","author":"F Ortiz-Sanju\u00e1n","year":"2015","unstructured":"Ortiz-Sanju\u00e1n F, Blanco R, Riancho-Zarrabeitia L, Casta\u00f1eda S, Oliv\u00e9 A, Riveros A et al (2015) Efficacy of anakinra in refractory adult-onset still\u2019s disease: multicenter study of 41 patients and literature review. Medicine (Baltimore) 94(39):e1554","journal-title":"Medicine (Baltimore)"},{"key":"3766_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead514","author":"B Kilic","year":"2023","unstructured":"Kilic B, Guler Y, Azman FN, Bostanc\u0131 E, Ugurlu S (2023) Efficacy and safety of anti-\u0131nterleukin-1 treatment in familial Mediterranean fever patients: a systematic review and meta-analysis. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/kead514","journal-title":"Rheumatology (Oxford)."},{"issue":"3","key":"3766_CR26","first-page":"92","volume":"8","author":"ND Tank","year":"2017","unstructured":"Tank ND, Karelia BN, Vegada BN (2017) Biological response modifiers in rheumatoid arthritis: systematic review and meta-analysis of safety. J Pharmacol Pharmacother 8(3):92\u2013105","journal-title":"J Pharmacol Pharmacother"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-024-03766-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-024-03766-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-024-03766-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T12:37:45Z","timestamp":1738672665000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-024-03766-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3766"],"URL":"https:\/\/doi.org\/10.1007\/s11739-024-03766-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4103455\/v1","asserted-by":"object"}]},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]},"assertion":[{"value":"15 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Serdal Ugurlu has received research grants from SOBI, the other co-authors have declared no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}